[{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Lens Pharma Expands Its Scientific Advisory Board","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Famar Health Care Services Madrid","sponsor":"Medicom Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicom Healthcare Ltd Announces the Signing of an Asset Purchase Agreement of BIMATOPROST 0.3 mg\/mL, 3ml","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Raises \u20ac10 Million in Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FAMAR and Medicom Healthcare Announce The Acquisition By Medicom Of The Pharmaceutical Dossier Of BIMATOPROST","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Mr. Doug Janzen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Financing to Support Launch of Zimed\u00ae Preservative - Free (Bimatoprost 0.03%) and Board Update","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed\u00ae PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediPrint\u2122 Ophthalmics Announces Initial Series A Funding Success","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","amount":"$32.8 million","upfrontCash":"$3.2 million","newsHeadline":"Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Receives FDA Approval for DURYSTA\u2122 (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to Lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPrint\u2122 Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Canadian Filing of NDS for Preservative - Free Glaucoma Medication","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyGlass Pharma Initiates Phase I\/II Clinical Trial of its Intraocular Drug Delivery Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets US FDA Approval for Generic Latisse Ophthalmic Solution","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPrint\u00ae Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Bimatoprost
DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure in patients with open angle glaucoma or high eye pressure (ocular hypertension), approved by the FDA in March 2020.
DURYSTA™ is a prostaglandin analog indicated for the reduction of IOP in patients with OAG or OHT. DURYSTA™ is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable implant containing 10 mcg bimatoprost.
A New Drug Application (NDA) for Bimatoprost SR is currently under review with the U.S. Food and Drug Administration, and if approved, has the potential to be the first and only biodegradable.
SpyGlass platform is - bimatoprost implanted with the SpyGlass intraocular lens (IOL) which is designed to deliver three years of bimatoprost sustained delivery for glaucoma management.
LL-BMT1 are contact lenses printed with bimatoprost which is a prostaglandin for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
The agreement granting Kowa to focus on the development and commercialization of NCX470 (bimatoprost), Nicox’s nitric oxide, which is used for the lowering of intraocular pressure in patients with glaucoma or ocular hypertension.
SpyGlass platform is - bimatoprost implanted with the SpyGlass intraocular lens (IOL) which is designed to deliver three years of bimatoprost sustained delivery for glaucoma management.
The financing will be used to advance novel treatments for glaucoma and other chronic ophthalmic diseases, including Bimatoprost, a prostaglandin analogue.
The net proceeds from the financing will be used to support the launch of Zimed PF (bimatoprost) for the reduction of elevated intraocular pressure (IOP) in patients with open - angled glaucoma or ocular hypertension.
Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Contact Supplier
